Intratumorally injected yeast vaccine
Disclosed herein are compositions and methods for treating solid tumors with yeast-based formulations.
1 . A composition for injection into a solid tumor, wherein the composition comprises effective amounts of a yeast and/or a lysate thereof, a checkpoint inhibitor selected from the group consisting of an anti-CTLA-4 antibody and an anti-PDL1 antibody, and an immunostimulatory protein selected from the group consisting of an Ox40 receptor agonist and nogapendkin-alfa-inbakicept (NAI; N-803).
2 . The composition of claim 1 , wherein the yeast is Saccharomyces cerevisiae.
3 . The composition of claim 1 , wherein the yeast is genetically engineered to express a tumor associated antigen, tumor specific antigen, or a neoepitope.
4 . The composition of claim 1 , wherein the Ox40 receptor agonist is a monoclonal antibody or a receptor ligand.
5 . The composition of claim 1 , wherein the tumor is a mucosal tumor, melanoma, a lung tumor or a colorectal tumor.
6 . The composition of claim 1 , wherein the tumor is metastatic.
7 . The composition of claim 1 , wherein the yeast is genetically engineered to express protein G on the surface of the yeast.
8 . The composition of claim 7 , wherein the Ox40 receptor agonist is an Fc-agonist fusion protein, and wherein the Fc-agonist fusion protein is bound to the yeast prior to administration.
9 . A method of treating a solid tumor, the method comprising intratumoral injection of an effective amount of a composition comprising a yeast and/or a lysate thereof, a checkpoint inhibitor selected from the group consisting of an anti-CTLA-4 antibody and an anti-PDL1 antibody, and an immunostimulatory protein selected from the group consisting of an Ox40 receptor agonist and nogapendkin-alfa-inbakicept (NAI; N-803).
10 . The method of claim 9 , wherein the yeast is Saccharomyces cerevisiae.
11 . The method of claim 9 , wherein the yeast is genetically engineered to express a tumor associated antigen, tumor specific antigen, or a neoepitope.
12 . The method of claim 9 , wherein the Ox40 receptor agonist is a monoclonal antibody or a receptor ligand.
13 . The method of claim 9 , wherein the tumor is a mucosal tumor, melanoma, a lung tumor or a colorectal tumor.
14 . The method of claim 9 , wherein the tumor is metastatic.
15 . The method of claim 9 , wherein the yeast is genetically engineered to express protein G on the surface of the yeast.
16 . The method of claim 15 , wherein the Ox40 receptor agonist is an Fc-agonist fusion protein, and wherein the Fc-agonist fusion protein is bound to the yeast prior to administration.